Cargando…
Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
Parental prostacyclin is the only therapy with a proven survival benefit in pulmonary arterial hypertension (PAH). However, some patients are unable to tolerate continuous prostacyclin infusion because of central line infection, side effects, or sociocultural factors. Selexipag is a recently approve...
Autores principales: | Holthaus, Nathan, Prins, Kurt W., Rose, Lauren, Prisco, Sasha, Pritzker, Marc, Thenappan, Thenappan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681254/ https://www.ncbi.nlm.nih.gov/pubmed/31215322 http://dx.doi.org/10.1177/2045894019862167 |
Ejemplares similares
-
Comparison of Balloon Pulmonary Angioplasty and Pulmonary Vasodilators for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Meta-Analysis
por: Kalra, Rajat, et al.
Publicado: (2020) -
Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2020) -
Sex differences in right ventricular function between Groups 1 and 3 pulmonary hypertension
por: Kazmirczak, Felipe, et al.
Publicado: (2023) -
With No Lysine Kinase 1 Promotes Metabolic Derangements and RV Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2021) -
Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis
por: Prins, Kurt W., et al.
Publicado: (2017)